What is YBRAIN?
YBRAIN operates at the intersection of biotechnology and digital health, specializing in the development and commercialization of electronic drugs designed to alleviate depression. The company's core value proposition lies in its ability to provide safe, convenient, and clinically validated mental health solutions. Through its flagship products, MINDD SCAN and MINDD STIM+, YBRAIN offers a comprehensive ecosystem that empowers both healthcare providers and patients. By focusing on neuroscience-based innovation, the company addresses the critical need for scalable mental health care, moving beyond conventional pharmaceutical approaches to offer targeted, technology-driven relief for patients suffering from mood disorders.
How much funding has YBRAIN raised?
YBRAIN has raised a total of $3.5M across 1 funding round:
Series A
$3.5M
Series A (2014): $3.5M with participation from Stonebridge Capital
Key Investors in YBRAIN
Stonebridge Capital
Stonebridge Capital is a financial services firm focused on personalized investment planning, asset protection, and long-term wealth creation strategies for its clients.
What's next for YBRAIN?
Looking ahead, YBRAIN is poised to leverage its recent financing to accelerate the clinical adoption of its electronic drug platform. The strategic focus will likely center on expanding the footprint of MINDD STIM+ within clinical settings and enhancing the user experience of its at-home care solutions. As the regulatory landscape for digital therapeutics continues to evolve, YBRAIN's commitment to rigorous clinical trials and data-driven outcomes will be paramount in securing long-term market dominance. The company is expected to prioritize partnerships with healthcare providers to integrate its technology into standard psychiatric care protocols, thereby cementing its role as a leader in the burgeoning field of neuro-modulation and mental health technology.
See full YBRAIN company page
